Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$30.29+0.43 (+1.44%)
Close on Nov 13, 2026Market cap $3.38BP/E –Yield –
Amylyx Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Amylyx Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2024 was 92.2%. For fiscal 2024 it was 93.2%, against 93.3% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 93.2% | −0.1 |
| FY2023 | Dec 31, 2023 | 93.3% | +6.8 |
| FY2022 | Dec 31, 2022 | 86.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | 100.0% | +5.7 |
| Q1 FY2024 | Mar 31, 2024 | 93.3% | +0.7 |
| Q4 FY2023 | Dec 31, 2023 | 91.4% | +4.3 |
| Q3 FY2023 | Sep 30, 2023 | 94.9% | +44.8 |
| Q2 FY2023 | Jun 30, 2023 | 94.3% | – |
| Q1 FY2023 | Mar 31, 2023 | 92.6% | – |
| Q4 FY2022 | Dec 31, 2022 | 87.1% | – |
| Q3 FY2022 | Sep 30, 2022 | 50.1% | – |
See a number that looks wrong?